Breaking News Instant updates and real-time market news.

AGN

Allergan

$166.31

1.25 (0.76%)

08:04
04/13/18
04/13
08:04
04/13/18
08:04

Allergan announces launch of TrueTear

Allergan announced the official launch of TrueTear, the first and only FDA-cleared device developed to temporarily increase tear production during neurostimulation in adult patients. The neurostimulation device will be officially launched during the 2018 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators annual meetings being held April 13-17 in Washington, DC.

  • 24

    Apr

  • 27

    Apr

  • 30

    Apr

  • 08

    May

AGN Allergan
$166.31

1.25 (0.76%)

03/14/18
RBCM
03/14/18
NO CHANGE
RBCM
Outperform
RBC says Allergan sent clear message that all strategic options being evaluated
RBC Capital analyst Randall Stanicky said that Allergan Chairman and CEO Brent Saunders and new CFO Matt Walsh sent a "clear" message while presenting earlier at an investor conference that all strategic options are being evaluated "with a sense of urgency." This message, which he said is the one he had hoped to hear, will keep the asset sale/break-up debate in the stock, said Stanicky. The analyst, who expects the Street's focus on asset sales to pick up following this, keeps an Outperform rating on Allergan shares.
03/15/18
JPMS
03/15/18
NO CHANGE
Target $265
JPMS
Overweight
Allergan CEO comments on evaluating options a 'clear positive,' says JPMorgan
JPMorgan analyst Chris Schott views Allergan CEO Brent Saunders' comments yesterday on evaluating all options to create value as a "clear positive." The company is focusing on core business execution with a set of near-term pipeline opportunities while also examining other potential value-unlocking options for the business, Schott tells investors in a research note. The analyst says he has long argued that Allergan's core business is "significantly undervalued" and that any shift toward greater Botox/aesthetics exposure would result in a company that trades at a "distinctly higher multiple" than the current business. As such, he believes selling or spinning off assets could unlock value. Schott keeps an Overweight rating on Allergan with a $265 price target.
03/26/18
WBLR
03/26/18
NO CHANGE
WBLR
Outperform
William Blair sees Biohaven safety as 'strong differentiator' versus Allergan
William Blair analyst Tim Lugo believes Biohaven Pharmaceutical's (BHVN) Phase III data this morning confirmed rimegepant's efficacy and "clean" safety profile. The analyst keeps an Outperform rating on the shares, which are trading down 29%, or $7.12, to $17.64. Lugo understands the focus on comparing today's results with the recent ubrogepant Phase III data from Allergan (AGN), but he notes that comparisons are complicated as Biohaven did not allow rescue medications or re-dosing. While the efficacy in Study 302 looked in line with Allergan's ubrogepant Phase III study, Study 301 looked to be affected by a higher placebo rate of a few percentage points, which negatively affected the difference versus placebo, Lugo tells investors in a research note. He believes safety for rimegepant is "impressive" and likely a " William Blair sees Biohaven safety as 'strong differentiator' versus AllerganWhile a drop-off in efficacy between Phase II and Phase III results is common, it may have been exacerbated as management noted the rimegepant formulation in the Phase III took 30 minutes longer to reach serum maximal concentration than the formulation used in Phase II, Lugo points out. Further, he thinks the profile of rimegepant could be boosted by the company's Phase III trial of a rapidly dissolving sublingual rimegepant formulation using Catalent's (CTLT) Zydis technology, which the analyst says should lead to a faster bioavailability.
04/12/18
DBAB
04/12/18
NO CHANGE
Target $212
DBAB
Buy
Deutsche Bank likes current setup for shares of Allergan
Allergan shares at current levels likely reflect concerns about the growth and durability of core franchises, low expectations for current pipeline assets, and skepticism about the company's ability to bolster the pipeline, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. His $212 price target includes value for only four late-stage pipeline assets, each with validating events in 2018. Removing these assets would reduce his target to $183, all else equal. Not all of the programs are likely to fail, Gilbert argues. As such, he likes the setup for the stock from here in the event of positive pipeline news and strong operational performance. He keeps a Buy rating on Allergan.

TODAY'S FREE FLY STORIES

XERS

Xeris Pharmaceuticals

$18.26

-0.18 (-0.98%)

06:53
07/16/18
07/16
06:53
07/16/18
06:53
Initiation
Xeris Pharmaceuticals initiated  »

Xeris Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INST

Instructure

$44.93

-0.225 (-0.50%)

06:53
07/16/18
07/16
06:53
07/16/18
06:53
Initiation
Instructure initiated  »

Instructure initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 30

    Jul

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:53
07/16/18
07/16
06:53
07/16/18
06:53
Hot Stocks
Bank of America CEO says solid operating leverage drove earnings in Q2 »

Brian Moynihan, Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

USO

United States Oil Fund

$14.47

0.085 (0.59%)

06:53
07/16/18
07/16
06:53
07/16/18
06:53
Technical Analysis
United States Oil Fund: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IIIV

i3 Verticals

$16.73

-0.025 (-0.15%)

06:52
07/16/18
07/16
06:52
07/16/18
06:52
Initiation
i3 Verticals initiated  »

i3 Verticals initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRYS

Krystal Biotech

$17.14

0.08 (0.47%)

06:52
07/16/18
07/16
06:52
07/16/18
06:52
Conference/Events
Krystal Biotech management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 25

    Jul

XOP

SPDR Oil Exploration and Production Fund

$43.19

0.06 (0.14%)

06:52
07/16/18
07/16
06:52
07/16/18
06:52
Technical Analysis
SPDR Oil Exploration and Production Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:51
07/16/18
07/16
06:51
07/16/18
06:51
Hot Stocks
Bank of America reports Q2 average loan balances in business segments up 5% »

Average loan balances in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

DGAZ

VelocityShares 3x Inv Natural Gas ETN

$26.43

0.89 (3.48%)

06:51
07/16/18
07/16
06:51
07/16/18
06:51
Technical Analysis
VelocityShares 3x Inv Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBIX

Neurocrine

$102.95

0.17 (0.17%)

, TEVA

Teva

$23.29

-0.45 (-1.90%)

06:51
07/16/18
07/16
06:51
07/16/18
06:51
Recommendations
Neurocrine, Teva analyst commentary  »

Neurocrine price target…

NBIX

Neurocrine

$102.95

0.17 (0.17%)

TEVA

Teva

$23.29

-0.45 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 10

    Sep

  • 16

    Sep

UGAZ

VelocityShares 3x Long Natural Gas ETN

$54.61

-2.06 (-3.64%)

06:50
07/16/18
07/16
06:50
07/16/18
06:50
Technical Analysis
VelocityShares 3x Long Natural Gas ETN: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:50
07/16/18
07/16
06:50
07/16/18
06:50
Hot Stocks
Bank of America reports Q2 NII up 6% to $11.7B »

Reflecting benefits from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

ERJ

Embraer

$21.50

-0.78 (-3.50%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Periodicals
Embraer sees demand for 10,550 smaller jets in next 20 years, Reuters reports »

Brazil's Embraer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

EPRT

Essential Properties Realty Trust

$14.00

(0.00%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Initiation
Essential Properties Realty Trust initiated  »

Essential Properties…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$34.05

0.67 (2.01%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Technical Analysis
MSCI Brazil Index: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VNTR

Venator Materials

$16.76

0.07 (0.42%)

, TROX

Tronox

$19.31

-0.28 (-1.43%)

06:49
07/16/18
07/16
06:49
07/16/18
06:49
Hot Stocks
Venator Materials to acquire European paper laminates business from Tronox »

Venator Materials (VNTR)…

VNTR

Venator Materials

$16.76

0.07 (0.42%)

TROX

Tronox

$19.31

-0.28 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 08

    Aug

PSA

Public Storage

$228.07

-1.43 (-0.62%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Downgrade
Public Storage rating change  »

Public Storage downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

EFA

iShares MSCI EAFE Index Fund

$67.80

0.21 (0.31%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Technical Analysis
iShares MSCI EAFE Index Fund: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$28.54

-0.24 (-0.83%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Hot Stocks
Bank of America reports Q2 return on average assets 1.17% »

Reports Q2 return on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

BRO

Brown & Brown

$28.76

0.025 (0.09%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Hot Stocks
Brown & Brown subsidiary acquires Professional Disability Associates »

J. Scott Penny, Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

JNK

SPDR Barclays High Yield Bond

$35.69

(0.00%)

06:48
07/16/18
07/16
06:48
07/16/18
06:48
Technical Analysis
SPDR Barclays High Yield Bond: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCI

Intra-Cellular

$20.45

-0.11 (-0.54%)

06:47
07/16/18
07/16
06:47
07/16/18
06:47
Conference/Events
Intra-Cellular management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

SJB

ProShares Short High Yield

$22.95

-0.055 (-0.24%)

06:47
07/16/18
07/16
06:47
07/16/18
06:47
Technical Analysis
ProShares Short High Yield: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSUR

OraSure

$17.32

0.01 (0.06%)

06:46
07/16/18
07/16
06:46
07/16/18
06:46
Downgrade
OraSure rating change  »

OraSure downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 08

    Aug

NEP

NextEra Energy Partners

$45.91

-0.51 (-1.10%)

06:46
07/16/18
07/16
06:46
07/16/18
06:46
Downgrade
NextEra Energy Partners rating change  »

NextEra Energy Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.